|
Sign In to gain access to subscriptions and/or personal tools.
|
Structure, Function, Expression, Genomic Organization, and Single Nucleotide Polymorphisms of Human ABCB1 (MDR1), ABCC (MRP), and ABCG2 (BCRP) Efflux Transporters
Supratim Choudhuri
Division of Biotechnology and GRAS Notice Review, Office of Food Additive Safety, Center for Food Safety and Nutrition, U.S. Food and Drug Administration, College Park, Maryland, USA
Curtis D. Klaassen
Department of Pharmacology, Toxicology and Therapeutics, University of Kansas Medical Center, Kansas City, Kansas, USA
Correspondence: Address correspondence to Supratim Choudhuri, PhD, CFSAN/OFAS/DBGNR, U.S. Food and Drug Administration, 5100 Paint Branch Parkway, HFS-255, College Park, MD 20740, USA. E-mail:Supratim.Choudhuri{at}fda.hhs.gov
The ATP-binding cassette (ABC) transporters constitute a large family of membrane proteins, which transport a variety of compounds through the membrane against a concentration gradient at the cost of ATP hydrolysis. Substrates of the ABC transporters include lipids, bile acids, xenobiotics, and peptides for antigen presentation. As they transport exogenous and endogenous compounds, they reduce the body load of potentially harmful substances. One by-product of such protective function is that they also eliminate various useful drugs from the body, causing drug resistance. This review is a brief summary of the structure, function, and expression of the important drug resistance–conferring members belonging to three subfamilies of the human ABC family; these are ABCB1 (MDR1/P-glycoprotein of subfamily ABCB), subfamily ABCC (MRPs), and ABCG2 (BCRP of subfamily ABCG), which are expressed in various organs. In the text, the transporter symbol that carries the subfamily name (such as ABCB1, ABCC1, etc.) is used interchangeably with the corresponding original names, such as MDR1/P-glycoprotein, MRP1, etc., respectively. Both nomenclatures are maintained in the text because both are still used in the transporter literature. This helps readers relate various names that they encounter in the literature. It now appears that P-glycoprotein, MRP1, MRP2, and BCRP can explain the phenomenon of multidrug resistance in all cell lines analyzed thus far. Also discussed are the gene structure, regulation of expression, and various polymorphisms in these genes. Because genetic polymorphism is thought to underlie interindividual differences, including their response to drugs and other xenobiotics, the importance of polymorphism in these genes is also discussed.
Key Words: P-glycoprotein MDR MRP BCRP Expression Localization SNP Function
International Journal of Toxicology, Vol. 25, No. 4,
231-259 (2006)
DOI: 10.1080/10915810600746023

CiteULike Complore Connotea Del.icio.us Digg Reddit Technorati Twitter What's this?
This article has been cited by other articles:

|
 |

|
 |
 
C. Giraud, S. Manceau, X. Decleves, F. Goffinet, J.-P. Morini, H. Chappuy, F. Batteux, S. Chouzenoux, S. Yousif, J.-M. Scherrmann, et al.
Influence of Development, HIV Infection, and Antiretroviral Therapies on the Gene Expression Profiles of ABC Transporters in Human Lymphocytes
J. Clin. Pharmacol.,
February 1, 2010;
50(2):
226 - 230.
[Abstract]
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
G. Ahlin, C. Hilgendorf, J. Karlsson, C. A.-K. Szigyarto, M. Uhlen, and P. Artursson
Endogenous Gene and Protein Expression of Drug-Transporting Proteins in Cell Lines Routinely Used in Drug Discovery Programs
Drug Metab. Dispos.,
December 1, 2009;
37(12):
2275 - 2283.
[Abstract]
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
L. Bousquet, A. Pruvost, A.-C. Guyot, R. Farinotti, and A. Mabondzo
Combination of Tenofovir and Emtricitabine plus Efavirenz: In Vitro Modulation of ABC Transporter and Intracellular Drug Accumulation
Antimicrob. Agents Chemother.,
March 1, 2009;
53(3):
896 - 902.
[Abstract]
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
M. Serrano-Sanchez, Z. Tanfin, and D. Leiber
Signaling Pathways Involved in Sphingosine Kinase Activation and Sphingosine-1-Phosphate Release in Rat Myometrium in Late Pregnancy: Role in the Induction of Cyclooxygenase 2
Endocrinology,
September 1, 2008;
149(9):
4669 - 4679.
[Abstract]
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
J. A. Williams, T. Andersson, T. B. Andersson, R. Blanchard, M. O. Behm, N. Cohen, T. Edeki, M. Franc, K. M. Hillgren, K. J. Johnson, et al.
PhRMA White Paper on ADME Pharmacogenomics
J. Clin. Pharmacol.,
July 1, 2008;
48(7):
849 - 889.
[Abstract]
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
Y. Kitamura, H. Koto, S. Matsuura, T. Kawabata, H. Tsuchiya, H. Kusuhara, H. Tsujimoto, and Y. Sugiyama
Modest Effect of Impaired P-glycoprotein on the Plasma Concentrations of Fexofenadine, Quinidine, and Loperamide following Oral Administration in Collies
Drug Metab. Dispos.,
May 1, 2008;
36(5):
807 - 810.
[Abstract]
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
C. M. Rudin, W. Liu, A. Desai, T. Karrison, X. Jiang, L. Janisch, S. Das, J. Ramirez, B. Poonkuzhali, E. Schuetz, et al.
Pharmacogenomic and Pharmacokinetic Determinants of Erlotinib Toxicity
J. Clin. Oncol.,
March 1, 2008;
26(7):
1119 - 1127.
[Abstract]
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
D. A. Evseenko, P. Murthi, J. W. Paxton, G. Reid, B. S. Emerald, K. M. Mohankumar, P. E. Lobie, S. P. Brennecke, B. Kalionis, and J. A. Keelan
The ABC transporter BCRP/ABCG2 is a placental survival factor, and its expression is reduced in idiopathic human fetal growth restriction
FASEB J,
November 1, 2007;
21(13):
3592 - 3605.
[Abstract]
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
A. Sayeed, S. D. Konduri, W. Liu, S. Bansal, F. Li, and G. M. Das
Estrogen Receptor {alpha} Inhibits p53-Mediated Transcriptional Repression: Implications for the Regulation of Apoptosis
Cancer Res.,
August 15, 2007;
67(16):
7746 - 7755.
[Abstract]
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
D. S. Streetman
Clinical Pharmacogenetics of the Major Adenosine Triphosphate Binding Cassette and Solute Carrier Drug Transporters
Journal of Pharmacy Practice,
June 1, 2007;
20(3):
219 - 233.
[Abstract]
[PDF]
|
 |
|

|
 |

|
 |
 
K. E. Estes, K. H. Busse, and S. R. Penzak
Pharmacogenetic Considerations in the Management of HIV Infection
Journal of Pharmacy Practice,
June 1, 2007;
20(3):
234 - 245.
[Abstract]
[PDF]
|
 |
|
|
|